Opus Genetics, Inc
Clinical trials sponsored by Opus Genetics, Inc, explained in plain language.
Gene therapy company developing treatments for inherited retinal diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Gene therapy injection aims to halt rare blindness
Disease control Recruiting nowThis early-stage trial tests a gene therapy called OPGx-BEST1 for two rare inherited eye diseases that cause vision loss. About 10 adults will receive a single injection into one eye to see if it is safe and to find the best dose. The study will follow participants for 5 years to…
Phase 1/2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental gene injection aims to halt rare childhood blindness
Disease control Recruiting nowThis study tests a gene therapy called OPGx-001 for people with vision loss caused by LCA5 gene mutations. The treatment is a one-time injection under the retina. The goal is to see if it is safe and can slow or stop vision loss. The study involves 22 participants aged 4 and olde…
Phase 1/2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC